|
Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact
|
|||||||||||
| Preis** (Lieferformat): |
Versandkostenfrei ** WICHTIG: Alle Preise sind netto ausgewiesen. Abhängig von Versand- und Leistungsort ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Der korrekte Gesamtendpreis wird Ihnen mit der Angabe Ihrer Rechnungsadresse, USt-ID-Nr. etc. im Bestellverlauf ausgewiesen. Weitere Informationen zu den Bestandteilen des Kaufpreises finden Sie in unseren FAQs. |
|||||||||||
| Zahlen und Fakten zur Studie: |
Reasons to Purchase *Review the clinical and commercial factors driving new product decisions in influenza vaccines and the strategies of key players in the market *Size the market with patient-based scenario forecasts of the seasonal vaccines market and a thorough analysis of the vaccine and antiviral pipeline *Understand concerns, unmet needs and future opportunities in influenza prevention and therapy 330 seiten | |||||||||||
| Inhalt der Studie: |
Introduction
Fuelled by the pandemic flu threat, the influenza market has expanded rapidly in recent years. This growing commercial opportunity has encouraged companies to develop new technologies an.....
Introduction Fuelled by the pandemic flu threat, the influenza market has expanded rapidly in recent years. This growing commercial opportunity has encouraged companies to develop new technologies and increase manufacturing capacity for influenza vaccines and antivirals. The H1N1 pandemic will stimulate further growth, but also confronts industry and public health stakeholders with new challenges. Scope *Strategic analysis of the current influenza market across the US, Japan, France, Germany, Italy, Spain and the UK and of key companies in the sector *Thorough assessment of commercial and clinical factors influencing and shaping the influenza treatment and prevention market *Patient-based forecast model for the seasonal flu vaccine market with three different scenarios modelling the long-term impact of the current pandemic *In-depth analysis of both influenza vaccine and antiviral pipeline candidates and discussion of their future potential Highlights The influenza sector has benefited from the increased disease awareness and funding due to the pandemic flu scare. Maintaining this momentum in the coming years will be a key challenge. New technologies in manufacturing, adjuvants and delivery will drive increased product differentiation in the currently highly commoditized flu vaccines market. Datamonitor believes that the most likely scenario for the long-term impact of the current H1N1 pandemic is a transient boost for seasonal flu vaccination, expanding the 7 major markets' size from $2.8 billion in 2008/2009 to over $4 billion in 2010/2011, followed by a period of stagnation caused by immunization fatigue. While Tamiflu will remain the leading influenza antiviral for the foreseeable future, resistance is becoming an increasing issue for Roche's drug. Biocryst's Phase III drug peramivir could claim an attractive niche market in hospitalized patients, while Biota's inhaled pipeline candidate CS-8958 has an interesting long-acting profile. Reasons to Purchase *Review the clinical and commercial factors driving new product decisions in influenza vaccines and the strategies of key players in the market *Size the market with patient-based scenario forecasts of the seasonal vaccines market and a thorough analysis of the vaccine and antiviral pipeline *Understand concerns, unmet needs and future opportunities in influenza prevention and therapy Report Highlights Highlights The influenza sector has benefited from the increased disease awareness and funding due to the pandemic flu scare. Maintaining this momentum in the coming years will be a key challenge. New technologies in manufacturing, adjuvants and delivery will drive increased product differentiation in the currently highly commoditized flu vaccines market. Datamonitor believes that the most likely scenario for the long-term impact of the current H1N1 pandemic is a transient boost for seasonal flu vaccination, expanding the 7 major markets' size from $2.8 billion in 2008/2009 to over $4 billion in 2010/2011, followed by a period of stagnation caused by immunization fatigue. While Tamiflu will remain the leading influenza antiviral for the foreseeable future, resistance is becoming an increasing issue for Roche's drug. Biocryst's Phase III drug peramivir could claim an attractive niche market in hospitalized patients, while Biota's inhaled pipeline candidate CS-8958 has an interesting long-acting profile. [Studien Infos ausblenden] |
|||||||||||
|
DATAMONITOR HEALTHCARE 2 About the Infectious diseases pharmaceutical analysis team 2 CHAPTER 1 EXECUTIVE SUMMARY 3 Strategic scoping and focus 3 Datamonitor insight into the influenza market 3 Related reports 6 Upcoming related reports 6 CHAPTER 2 MARKET DEFINITION 8 Market definition for this report 8 CHAPTER 3 SEASONAL INFLUENZA VACCINE MARKET OVERVIEW AND FORECAST 10 Seven major markets 10 Current and future market overview 10 Vaccination recommendations 11 Vaccination coverage rates 13 Opportunities and threats 13 Opportunities 13 Threats 19 Forecast to 2018/19 20 US 23 Current market assessment 23 Vaccination recommendations 26 Vaccination coverage rates 27 Opportunities and threats 34 Opportunities 35 Threats 45 Forecast to 2018/19 50 Japan 54 Current and future market assessment 54 Vaccination recommendations 55 Vaccination coverage rates 56 Opportunities and threats 57 Opportunities 58 Threats 60 Forecast to 2018/19 61 Five major European markets (5EU) 64 Current and future market assessment 64 Vaccination recommendations 65 Vaccination coverage rates 69 Opportunities and threats 74 Opportunities 75 Threats 77 Forecast to 2018/19 77 France 79 Current and future market assessment 79 Vaccination recommendations 82 Vaccination coverage rates 84 Forecast to 2018/19 87 Germany 91 Current and future market assessment 91 Vaccination recommendations 95 Vaccination coverage rates 96 Forecast to 2018/19 98 Italy 102 Current and future market assessment 102 Vaccination recommendations 103 Vaccination coverage rates 104 Forecast to 2018/19 105 Spain 109 Current and future market assessment 109 Vaccination recommendations 111 Vaccination coverage rates 113 Forecast to 2018/19 114 UK 117 Current and future market assessment 117 Vaccination recommendations 119 Vaccination coverage rates 121 Forecast to 2018/19 123 Rest of the world snapshot 127 Current market assessment 127 Unmet needs 129 Vaccines with increased efficacy in the elderly constitute the largest unmet need 130 Experts still see a need for novel influenza treatment and prevention strategies 132 Needle-free administration techniques could make vaccination faster and more convenient 133 Faster and more flexible manufacturing technologies are particularly important for pandemic vaccine supply 134 Antigen sparing is a key focus for pandemic vaccination 136 Improved efficacy in children is considered less important by most experts 137 CHAPTER 4 INFLUENZA VACCINES - KEY DEVELOPERS, PRODUCTS AND STRATEGIES 138 Strategic Overview 138 Trends in corporate strategy 139 Improved immunogenicity, particularly in the elderly, is a key development focus 140 Alternative delivery routes could increase convenience and efficacy 141 Manufacturing capacity continues to play an important role for corporate strategies 142 Vaccine manufacturers are looking to expand to additional geographies 144 Pandemic vaccines offer government funding and stockpiling opportunities 145 Sanofi Pasteur - the market leaders 146 Corporate strategy overview 146 Influenza portfolio assessment 149 Seasonal influenza vaccines 149 Pandemic influenza vaccines (excluding influenza A(H1N1)) 153 Manufacturing capacity 155 Adjuvants 156 Strategic outlook 157 Novartis - the innovators 158 Corporate strategy overview 158 Influenza portfolio assessment 159 Seasonal influenza vaccines 159 Fluvirin 161 Agrippal S1 162 Fluad/Adiugrip 162 Begrivac 163 Optaflu 164 Pandemic influenza vaccines (excluding influenza A(H1N1)) 164 Manufacturing capacity 167 Adjuvants 167 Strategic outlook 168 GlaxoSmithKline - the lucky third 170 Corporate strategy overview 170 Influenza portfolio assessment 173 Seasonal influenza vaccines 173 Pandemic influenza vaccines (excluding influenza A(H1N1)) 178 Manufacturing capacity 180 Adjuvants 180 Strategic outlook 181 AstraZeneca/MedImmune - the niche players 182 Corporate strategy 182 Influenza portfolio assessment 184 Seasonal influenza vaccines 184 Pandemic influenza vaccines (excluding influenza A(H1N1)) 189 Manufacturing capacity 190 Adjuvants 191 Strategic outlook 191 CSL - the southern stars 193 Corporate strategy 193 Influenza portfolio assessment 194 Seasonal influenza vaccines 194 Pandemic influenza vaccines (excluding influenza A(H1N1)) 195 Manufacturing capacity 197 Adjuvants 197 Strategic outlook 198 Solvay - looking east 199 Corporate strategy 199 Influenza portfolio assessment 201 Seasonal influenza vaccines 201 Pandemic influenza vaccines (excluding influenza A(H1N1)) 204 Manufacturing capacity 205 Adjuvants 206 Strategic outlook 206 Portfolio assessment of other leading companies 207 Other seasonal vaccines in development 207 Other marketed seasonal influenza vaccines 208 Other pipeline seasonal influenza vaccines 209 Other pandemic vaccines in clinical development (excluding influenza A(H1N1)) 214 CHAPTER 5 INFLUENZA ANTIVIRALS 218 Overview of competitive landscape 218 US 223 Japan 223 5EU 224 Tamiflu (oseltamivir; Roche) 226 Drug profile 226 Commercial perspective 227 SWOT analysis and outlook 230 Relenza (zanamivir; GlaxoSmithKline) 233 Drug profile 233 Commercial perspective 234 SWOT analysis 236 Drivers of brand choice 238 Tamiflu offers a more convenient mode of administration 238 Relenza's better resistance profile could increase the drug's market share 239 Reports linking Tamiflu with neuropsychiatric events are perceived negatively by parts of the medical community 240 Outlook - balancing of stockpiles likely 241 US formulary tier status for leading brands 242 Trends in marketing strategies 243 Marketing strategy for leading influenza antivirals 243 Tamiflu 244 Relenza 245 Promotional spend 245 Unmet needs 247 Pipeline influenza antivirals 249 Peramivir (Biocryst, Shionogi, Green Cross) 249 Drug profile 250 Development overview 251 Product positioning 253 SWOT analysis 253 CS-8958 (Biota, Daiichi Sankyo) 254 Drug profile 255 Development overview 256 Product positioning 259 SWOT analysis 259 Favipiravir/T-705 (Toyama) 260 Drug profile 261 Innovative early stage compounds 263 CHAPTER 6 THE 2009 INFLUENZA A(H1N1) PANDEMIC 265 Background and timeline 265 Over the last century, three influenza A pandemics have occurred 265 The current influenza A(H1N1) pandemic continues to spread rapidly across the globe 266 Antivirals 270 Key challenges for antiviral therapy of influenza A(H1N1) 270 The emergence of resistances against antivirals, including Tamiflu, is a major risk 270 Supply shortages are likely if influenza antivirals are used without sufficient consideration 270 Compulsory licensing for influenza antivirals could become a threat in emerging and developing countries 272 Vaccination against influenza A(H1N1) 272 Key challenges for vaccine development and administration against influenza A(H1N1) 273 Lack of manufacturing capacity is likely to result in undersupply of pandemic vaccine 273 Timely production and administration of a vaccine will be crucial 276 The organization of a seamless supply chain will be the greatest challenge in pandemic management 279 Costs will be an issue for developing countries 281 Key needs with regards to influenza A(H1N1) vaccine development and production 282 Safety and reactogenicity are the most important requirements for an influenza A(H1N1) vaccine 283 Fast manufacturing technologies remain a key need 284 Established influenza vaccine and treatment providers will draw the largest commercial benefit out of the current influenza(H1N1) pandemic 285 Novartis - indirect benefits for adjuvant technology expected 289 GlaxoSmithKline - the allrounders 290 Roche - relying on ongoing need for Tamiflu 292 Baxter - outpacing the competition in manufacturing 292 Sanofi Pasteur - set to gain from capacity lead 293 MedImmune - focusing on the US 294 CSL - Australia and beyond 295 There is room and need for other strategies such as universal vaccines or influenza antibodies 296 Success in universal influenza vaccine development has been limited so far 297 Influenza antibodies could provide a useful tool for the treatment of severe cases of influenza 300 BIBLIOGRAPHY 302 Literature 302 APPENDIX A - MARKET ASSUMPTIONS 322 Data definitions, limitations and assumptions 322 Standard units 322 Forecast methodology 322 Datamonitor forecast methodology 322 Datamonitor's patient-based forecasting model 323 Limitations of the patient-based forecasting model 325 APPENDIX B 326 Contributing experts 326 Conferences attended 326 Report methodology 326 About Datamonitor 327 About Datamonitor Healthcare 327 About the Infectious Diseases analysis team 328 Key therapy team members 329 Holger Rovini, Head of Respiratory and Infectious Diseases 329 Hedwig Kresse, Senior Analyst, Infectious Diseases 329 Disclaimer 330 [Inhaltsverzeichnis ausblenden] |
||||||||||||
|
List of Tables Table 1: Influenza vaccine recommendations, seven major markets, 2009 12 Table 2: Summary of opportunities and threats in the influenza market, seven major markets, 2009 13 Table 3: Seven major markets - seasonal influenza vaccine market forecast; 2005/06-2018/19 21 Table 4: Seasonal influenza vaccine recommendations in key target groups, US, 2009 27 Table 5: Summary of opportunities and threats in the inflammatory bowel disease market in the US, 2009 35 Table 6: Estimated influenza vaccination rates, US, 2009 43 Table 7: US - seasonal influenza vaccine market forecast; 2005/06-2018/19 51 Table 8: US - seasonal influenza vaccine coverage forecast; 2005/06-2018/19 53 Table 9: Currently marketed seasonal influenza vaccines, Japan, 2009 54 Table 10: Seasonal influenza vaccine recommendations for key target groups, Japan, 2009 56 Table 11: Summary of opportunities and threats in the influenza market, Japan, 2009 58 Table 12: Japan - seasonal influenza vaccine market forecast; 2005/06-2018/19 62 Table 13: Japan - seasonal influenza vaccine coverage forecast; 2005/06-2018/19 64 Table 14: National influenza vaccine recommendations for individuals suffering from underlying medical conditions (without regard to age); 5EU, 2009 67 Table 15: Summary of opportunities and threats in the influenza market, 5EU, 2009 75 Table 16: 5EU - seasonal influenza vaccine market forecast; 2005/06-2018/19 79 Table 17: Currently marketed seasonal influenza vaccines, France, 2009 80 Table 18: Influenza vaccine prices per dose, France, 2005-2008 81 Table 19: Seasonal influenza vaccine recommendations, France, 2009 83 Table 20: France - seasonal influenza vaccine market forecast; 2005/06-2018/19 89 Table 21: France - seasonal influenza vaccine coverage forecast; 2005/06-2018/19 91 Table 22: Currently approved and marketed seasonal influenza vaccines, Germany, 2009 93 Table 23: Influenza vaccine prices per dose, Germany, 2005-2008 94 Table 24: Seasonal influenza vaccine recommendations for key risk groups, Germany, 2009 96 Table 25: Germany - seasonal influenza vaccine market forecast; 2005/06-2018/19 100 Table 26: Germany - seasonal influenza vaccine coverage forecast; 2005/06-2018/19 101 Table 27: Currently marketed seasonal influenza vaccines, Italy, 2009 102 Table 28: Influenza vaccine prices per dose, Italy, 2005-2009 103 Table 29: Seasonal influenza vaccine recommendations for key risk groups, Italy, 2009 104 Table 30: Italy - seasonal influenza vaccine market forecast; 2005/06-2018/19 107 Table 31: Italy - seasonal influenza vaccine coverage forecast; 2005/06-2018/19 109 Table 32: Currently marketed seasonal influenza vaccines, Spain, 2009 110 Table 33: Seasonal influenza vaccine recommendations for key target groups, Spain, 2009 112 Table 34: Spain - seasonal influenza vaccine market forecast; 2005/06-2018/19 115 Table 35: Spain - seasonal influenza vaccine coverage forecast; 2005/06-2018/19 117 Table 36: Currently marketed seasonal influenza vaccines, UK, 2009 118 Table 37: Seasonal influenza vaccine recommendations for key risk groups, UK, 2009 120 Table 38: UK - seasonal influenza vaccine market forecast; 2005/06-2018/19 124 Table 39: UK - seasonal influenza vaccine coverage forecast; 2005/06-2018/19 126 Table 40: Recent investments in influenza vaccine manufacturing capacity; 2009 143 Table 41: Deals between major flu vaccine players in the Western world and local manufacturers in emerging markets 145 Table 42: Sanofi Pasteur - portfolio and pipeline overview seasonal influenza vaccines, 2009 150 Table 43: Sanofi Pasteur - portfolio and pipeline overview pandemic influenza vaccines (excluding H1N1), 2009 153 Table 44: Sanofi Pasteur - SWOT analysis for influenza franchise, 2009 158 Table 45: Novartis - portfolio and pipeline overview seasonal influenza vaccines, 2009 161 Table 46: Novartis - portfolio and pipeline overview pandemic influenza vaccines (excluding H1N1), 2009 165 Table 47: Novartis - SWOT analysis for influenza franchise, 2009 169 Table 48: GlaxoSmithKline - portfolio and pipeline overview seasonal influenza vaccines, 2009 174 Table 49: GlaxoSmithKline - portfolio and pipeline overview pandemic influenza vaccines (excluding H1N1), 2009 178 Table 50: GlaxoSmithKline - SWOT analysis for influenza franchise, 2009 182 Table 51: AstraZeneca/MedImmune - portfolio and pipeline overview seasonal influenza vaccines, 2009 184 Table 52: AstraZeneca/MedImmune - portfolio and pipeline overview pandemic influenza vaccines (excluding H1N1), 2009 189 Table 53: MedImmune - licensees for reverse genetics technology in influenza 192 Table 54: AstraZeneca/MedImmune - SWOT analysis for influenza franchise, 2009 193 Table 55: CSL - portfolio and pipeline overview seasonal influenza vaccines, 2009 194 Table 56: CSL - portfolio and pipeline overview pandemic influenza vaccines (excluding H1N1), 2009 196 Table 57: CSL - SWOT analysis for influenza franchise, 2009 199 Table 58: Solvay - portfolio and pipeline overview seasonal influenza vaccines, 2009 202 Table 59: Solvay - portfolio and pipeline overview pandemic influenza vaccines (excluding H1N1), 2009 204 Table 60: Solvay - SWOT analysis for influenza franchise, 2009 207 Table 61: Other marketed seasonal vaccines across the seven major markets, July 2009 209 Table 62: Other seasonal vaccines in clinical development across the seven major markets, July 2009 211 Table 63: Other pandemic vaccines in clinical development (excluding H1N1) across the seven major markets, July 2009 216 Table 64: Leading influenza antivirals in the seven major markets, 2009 218 Table 65: Tamiflu - drug profile, 2009 227 Table 66: Tamiflu - SWOT analysis 233 Table 67: Relenza - drug profile, 2009 234 Table 68: Relenza - SWOT analysis 237 Table 69: Representative formulary tier status in the US for leading influenza antivirals, 2009 243 Table 70: Marketing strategies employed by the companies behind the top two influenza antivirals, 2009 244 Table 71: Key influenza antivirals in late-stage R&D pipeline, 2009 249 Table 72: Peramivir - Drug profile, 2009 250 Table 73: Peramivir - clinical trial summary, 2009 252 Table 74: Peramivir - SWOT analysis 254 Table 75: CS-8958 - drug profile, 2009 256 Table 76: CS-8958 - clinical trial summary, 2009 258 Table 77: CS-8958 - SWOT analysis 260 Table 78: Favipiravir - drug profile, 2009 262 Table 79: Innovative early stage influenza antivirals, July 2009 263 Table 80: Historic influenza A pandemics 265 Table 81: Influenza A(H1N1) pandemic - timeline of events 267 Table 82: Influenza A(H1N1) - cases and deaths across the seven major markets, July 6, 2009 269 Table 83: Antiviral stockpiles across the seven major markets, July 2009 271 Table 84: Influenza A(H1N1) vaccine orders, seven major markets, July 2009 275 Table 85: Novartis - influenza A(H1N1) stockpiling deals, July 2009 289 Table 86: GlaxoSmithKline - influenza A(H1N1) stockpiling deals, July 2009 291 Table 87: Baxter - influenza A(H1N1) stockpiling deals, July 2009 293 Table 88: Sanofi Pasteur - influenza A(H1N1) stockpiling deals, July 2009 294 Table 89: MedImmune - influenza A(H1N1) stockpiling deals, July 2009 295 Table 90: CSL - influenza A(H1N1) stockpiling deals, July 2009 295 Table 91: Selected universal influenza vaccines in development, July 2009 298 List of Figures Figure 1: Geographic distribution of influenza vaccine production capacities, 2009 11 Figure 2: Global influenza vaccine manufacturing capacity, 1994-2008 14 Figure 3: Seven major markets - seasonal influenza vaccine market forecast; 2005/06-2018/19 21 Figure 4: Seasonal influenza vaccine market forecast by country; 2005/6-2018/19 22 Figure 5: Vaccine providers for the US market, 2000/2001-2008/2009 24 Figure 6: Seasonal influenza vaccine coverage rates by target group (1), US, 2005/06-2008/09 33 Figure 7: Seasonal influenza vaccine coverage rates by target group (2), US, 2005/06-2008/09 34 Figure 8: US government strategies to foster growth of the national flu vaccine market 36 Figure 9: Vaccine releases versus timepoint of vaccination, US, 2006/07 and 2007/08 39 Figure 10: Influenza vaccine supply versus demand, US, 2003/2004-2008/2009 46 Figure 11: Average seasonal influenza vaccine prices per dose, US, 2002-2009 49 Figure 12: US - seasonal influenza vaccine market forecast; 2005/06-2018/19 51 Figure 13: US - seasonal influenza vaccine population forecast; 2005/06 - 2018/19 53 Figure 14: Seasonal influenza vaccine coverage rates by target group, Japan, 2001/02-2005/06 57 Figure 15: Japan - seasonal influenza vaccine market forecast; 2005/06-2018/19 62 Figure 16: Japan - seasonal influenza vaccine population forecast; 2005/06-2018/19 63 Figure 17: Total number of seasonal influenza vaccine doses distributed in the 27 EU countries, seasons 2003/04-2007/08 65 Figure 18: Countries recommending seasonal influenza vaccination for the elderly; Europe, 2007 66 Figure 19: Number of countries recommending seasonal influenza vaccination, by medical condition; Europe, 2007 67 Figure 20: Countries recommending seasonal influenza vaccination for pregnant women; Europe, 2007 68 Figure 21: Countries recommending seasonal influenza vaccination for healthy household contacts; Europe, 2007 69 Figure 22: Influenza vaccine doses distributed per 100,000 inhabitants of the EU27 countries versus proportion of the population recommended for vaccination (EU25), seasons 2003/04-2007/08 70 Figure 23: Distribution of seasonal influenza vaccine doses per 100,000 inhabitants in EU27 countries, by country, seasons 2003-04 to 2007-08 70 Figure 24: Influenza vaccination rates for the elderly aged 65 years and older, 5EU, seasons 2006/07 and 2007/08 71 Figure 25: Influenza vaccination rates high-risk individuals aged <65 years, 5EU, seasons 2006/07 and 2007/08 72 Figure 26: Influenza vaccination rates in healthcare workers, 5EU, seasons 2006/07 and 2007/08 73 Figure 27: Vaccinated population by age group, 5EU, season 2006/07 74 Figure 28: Use of influenza mass media campaigns across Europe, 2007 76 Figure 29: 5EU - seasonal influenza vaccine market forecast; 2005/06-2018/19 78 Figure 30: Seasonal influenza vaccine coverage rates by target group, France, 2005/06-2008/09 86 Figure 31: France - seasonal influenza vaccine market forecast; 2005/06-2018/19 88 Figure 32: France - seasonal influenza vaccine population forecast; 2005/06-2018/19 90 Figure 33: Cumulative number of doses of seasonal influenza vaccine released, Germany, 2002/03-2008/09 92 Figure 34: Seasonal influenza vaccine coverage rates by target group, Germany, 2005/06-2008/09 98 Figure 35: Germany - seasonal influenza vaccine market forecast; 2005/06-2018/19 99 Figure 36: Germany - seasonal influenza vaccine population forecast; 2005/06-2018/19 101 Figure 37: Seasonal influenza vaccine coverage rates by target group, Italy, 2005/06-2008/09 105 Figure 38: Italy - seasonal influenza vaccine market forecast; 2005/06-2018/19 106 Figure 39: Italy - seasonal influenza vaccine population forecast; 2005/06-2018/19 108 Figure 40: Seasonal influenza vaccine coverage rates by target group, Spain, 2005/06-2008/09 113 Figure 41: Spain - seasonal influenza vaccine market forecast; 2005/06-2018/19 115 Figure 42: Spain - seasonal influenza vaccine population forecast; 2005/06-2018/19 116 Figure 43: Seasonal influenza vaccine coverage rates by target group, UK, 2005/06-2008/09 123 Figure 44: UK - seasonal influenza vaccine market forecast; 2005/06-2018/19 124 Figure 45: UK - seasonal influenza vaccine population forecast; 2005/06-2018/19 126 Figure 46: Influenza vaccine distribution globally and by WHO region 127 Figure 47: Evolution of seasonal influenza vaccine distribution by WHO region 128 Figure 48: Unmet needs in influenza prevention, 2009 130 Figure 49: Comparative positioning of the six leading influenza vaccine manufacturers, 2009 139 Figure 50: Trends in corporate strategy for influenza vaccine development, 2009 140 Figure 51: Sanofi Pasteur - influenza vaccine sales, 2004-2008 147 Figure 52: Sanofi Pasteur - share influenza vaccines of overall vaccine sales; 2004-2008 148 Figure 53: GlaxoSmithKline - influenza vaccine sales, 2004-2008 171 Figure 54: GlaxoSmithKline - influenza vaccines sales' share of overall vaccine sales; 2004-2008 172 Figure 55: AstraZeneca/MedImmune: FluMist sales, 2004-2008 183 Figure 56: FluMist versus injected influenza vaccines - CDC and private sector costs/dose in the US, 2002-08 187 Figure 57: Solvay - influenza vaccine sales, 2004-2008 200 Figure 58: Pipeline trends in influenza vaccines, June 2009 208 Figure 59: Pipeline focus for seasonal flu vaccine developers, 2009 210 Figure 60: Influenza antivirals - sales and volume use, 7MM, 2004-2008 219 Figure 61: Influenza antivirals - geographic split of sales and volume use, 7MM, 2004-2008 222 Figure 62: US - influenza antiviral market shares, 2004-2008 223 Figure 63: Japan - influenza antiviral market shares, 2004-2008 224 Figure 64: 5EU - influenza antiviral market shares, 2004-2008 225 Figure 65: Tamiflu - sales and volume use, seven major markets, 2004-2008 228 Figure 66: Seasonal versus pandemic sales for Tamiflu, global, Q1/2007-Q2/2009 229 Figure 67: Relenza - sales and volume use, seven major markets, 2004-2008 235 Figure 68: Drivers of brand choice for influenza antivirals, 2009 238 Figure 69: Promotional spend for leading influenza antivirals, seven major markets, 2005/06-2007/08 246 Figure 70: Type of promotional spend for leading influenza antivirals, seven major markets, 2005/06-2007/08 247 Figure 71: Unmet needs in influenza antiviral therapy, 2009 248 Figure 72: Favipiravir: mechanism of action 262 Figure 73: Confirmed influenza A(H1N1) cases globally, July 6, 2009 268 Figure 74: Datamonitor's patient-based vaccine forecasting model - influence factors 324 [Tabellenverzeichnis ausblenden] |
||||||||||||
| Hinweis: | * Der Rechnungsbetrag für diese Studie wird in $ (Dollar) ausgewiesen. Kunden aus dem Inland bekommen von uns eine Rechnung in Euro, umgerechnet zum letztwöchigen Schlusskurs | |||||||||||
|
|
||||||||||||
